Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

NCT00174343 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2011-04-22

No results posted yet for this study

Summary

To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)

Conditions

  • Breast Neoplasms

Interventions

DRUG

exemestane (Aromasin®)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30
Completion
2006-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00174343 on ClinicalTrials.gov